Letters to the Editor

Phase 1b dose-escalation study of the selective, noncovalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies

Weill Cornell Medicine, Department of Medicine, New York
Moffitt Cancer Center, Tampa, FL
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
Swedish Cancer Institute, Seattle, WA
Willamette Valley Cancer Institute/US Oncology, Eugene, OR
MD Anderson Cancer Center, Houston, TX
Moores Cancer Center, University of California San Diego, La Jolla, CA
Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, CA
Fred Hutchinson Cancer Research Center, Seattle, WA
CLL Center, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
Swedish Cancer Institute, Seattle, WA
Texas Oncology/US Oncology Research, Tyler, TX
Sunesis Pharmaceuticals, South San Francisco, CA
Sunesis Pharmaceuticals, South San Francisco, CA
Sunesis Pharmaceuticals, South San Francisco, CA
Combs Consulting Service, Mountain View, CA
Sunesis Pharmaceuticals, South San Francisco, CA
Weill Cornell Medicine, Department of Medicine, New York
CLL Center, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
Haematologica Early view Dec 23, 2021 https://doi.org/10.3324/haematol.2021.280061